5/22/2023

Adenosine Injection

Products Affected - Description

- Adenosine intravenous injection, Teva, 3 mg/mL, 20 mL vial, 1 count, NDC 00703-8776-01
- Adenosine intravenous injection, Teva, 3 mg/mL, 30 mL vial, 1 count, NDC 00703-8777-01
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 2 mL syringe, 10 count, NDC 63323-0651-89
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 2 mL vial, 10 count, NDC 63323-0651-02
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 4 mL syringe, 10 count, NDC 63323-0651-90
- Adenosine intravenous injection, Sagent, 3 mg/mL, 2 mL prefilled syringe, 10 count, NDC 25021-0301-67
- Adenosine intravenous injection, Sagent, 3 mg/mL, 4 mL prefilled syringe, 10 count, NDC 25021-0301-68

Reason for the Shortage

- Akorn ceased operations in February 2023.
- Pfizer discontinued adenosine in late-2022.
- Eugia has adenosine available.
- Fresenius Kabi did not provide a reason for the shortage.
- Sagent did not provide a reason for the shortage.
- Teva has adenosine on shortage due to manufacturing delays.
- Viatris has adenosine available.

Available Products

- Adenosine intravenous injection, Eugia US, 3 mg/mL, 20 mL vial, 1 count, NDC 55150-0192-01
- Adenosine intravenous injection, Eugia US, 3 mg/mL, 30 mL vial, 1 count, NDC 55150-0193-01
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 20 mL vial, 1 count, NDC 63323-0651-20
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 30 mL vial, 1 count, NDC 63323-0651-30
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 20 mL vial, 1 count, NDC 67457-0856-20
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 30 mL vial, 1 count, NDC 67457-0857-30
- Adenosine intravenous injection, Fresenius Kabi, 3 mg/mL, 4 mL vial, 10 count, NDC 63323-0651-04
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 2 mL vial, 10 count, NDC 67457-0855-02
- Adenosine intravenous injection, Mylan (Viatris), 3 mg/mL, 4 mL vial, 10 count, NDC 67457-0854-04
- Adenosine intravenous injection, Sagent, 3 mg/mL, 2 mL vial, 10 count, NDC 25021-0318-02
- Adenosine intravenous injection, Sagent, 3 mg/mL, 4 mL vial, 10 count, NDC 25021-0318-04

Estimated Resupply Dates

- Fresenius Kabi has adenosine 3 mg/mL 2 mL and 4 mL syringes on back order and the company estimates a release date of late-June 2023. The 3 mg/mL 2 mL vials are on back order and the company estimates a release date of late-May to early-June 20223.
- Sagent has short-dated adenosine 3 mg/mL 2 mL syringes available with an expiration date of August 2023. The 4 mL syringes are on back order and the company estimates a release date of June 2023.
- Teva has has adenosine 3 mg/mL 20 mL and 30 mL vials temporarily unavailable and the company cannot estimate a release date.

Updated

Updated May 22, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 3, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.